← Back to Search

Bupivacaine Liposome Injection [Exparel] for Traumatic Injury

Phase 4

Waitlist Available

Led By Chadrick R Evans, MD

Research Sponsored by Chadrick Evans

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

All patients 18 years of age or older suffering 3 or more rib fractures treated by University of Illinois College of Medicine at Peoria (UICOMP) attending or resident physicians at OSF St. Francis Medical Center (OSFMC) are potentially eligible for enrollment in the trial.

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up every 24hours for 96hours

Awards & highlights

Study Summary

This study is evaluating whether a new type of injection may help reduce pain for individuals with multiple rib fractures.

Eligible Conditions

Trauma
Traumatic Injury
Acute Pain

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ every 24hours for 96hours

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~every 24hours for 96hours

This trial's timeline: 3 weeks for screening, Varies for treatment, and every 24hours for 96hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in pain relief

Secondary outcome measures

Costs

ICU stay

Length of pain medication

+8 more

Trial Design

2Treatment groups

Active Control

Group I: Bupivacaine Liposome Injection [Exparel]Active Control1 Intervention

Patients will receive a nerve block with a medication called liposomal bupivacaine, also called Exparel. Once assigned, a University of Illinois surgeon, or resident surgeon, will administer the nerve block. The nerve block is expected to provide pain relief from 72 to 96 hours. During this time, patients may request oral or intravenous pain medication for breakthrough pain. Patients will remain in the hospital until discharged by the attending physician.

Group II: Epidural 0.125% bupivicaineActive Control1 Intervention

Patients will receive pain relief through a 0.125% bupivacaine epidural in the upper back by an assigned anesthesiologist. This epidural will remain in place for an uncertain amount of time. The decision to remove the epidural will be determined by the physicians and will be based on level of pain and injury. However, pain data will only be recorded by the research team for no longer than 96 hours after the epidural is placed. Patients are able to request intravenous and oral pain medications for breakthrough pain. After the epidural is removed, they will remain in the hospital until discharged by the attending physician.

0 / 1Eligibility criteria met